Teva Pharmaceutical Industries Limited (TLV:TEVA)
5,595.00
-95.00 (-1.67%)
Jul 31, 2025, 5:24 PM IDT
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $4.18B USD in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+2.07%
P/S Ratio
1.07
Revenue / Employee
$465.95K
Employees
35,686
Market Cap
60.21B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Danel (Adir Yeoshua) | 2.81B |
Kamada | 622.70M |
Bait Bakfar | 104.50M |
SofWave Medical | 235.09M |
BrainsWay | 161.81M |
Novolog (Pharm-Up 1966) | 2.07B |
Ilex Medical | 922.08M |
Epitomee Medical | 37.17M |
Teva Pharmaceutical Industries News
- 1 day ago - Teva CEO: Our supply chain puts us in a strong position - CNBC
- 1 day ago - Teva raises 2025 EPS outlook and innovative product guidance as company targets $700M in cost savings by 2027 - Seeking Alpha
- 1 day ago - Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Teva posts Q2 revenue miss as generic products underperform - Seeking Alpha
- 1 day ago - Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings - Investor's Business Daily
- 1 day ago - Teva Pharm Q2 profit beats estimates as branded drugs gain - Reuters
- 1 day ago - Teva Pharmaceutical Non-GAAP EPS of $0.66 beats by $0.04, revenue of $4.18B misses by $90M - Seeking Alpha
- 2 days ago - Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong - Benzinga